248 related articles for article (PubMed ID: 30803859)
1. FXR deficiency alters bile acid pool composition and exacerbates chronic alcohol induced liver injury.
Kong B; Zhang M; Huang M; Rizzolo D; Armstrong LE; Schumacher JD; Chow MD; Lee YH; Guo GL
Dig Liver Dis; 2019 Apr; 51(4):570-576. PubMed ID: 30803859
[TBL] [Abstract][Full Text] [Related]
2. FXR deletion in hepatocytes does not affect the severity of alcoholic liver disease in mice.
Zhang M; Kong B; Huang M; Wan R; Armstrong LE; Schumacher JD; Rizzolo D; Chow MD; Lee YH; Guo GL
Dig Liver Dis; 2018 Oct; 50(10):1068-1075. PubMed ID: 29730159
[TBL] [Abstract][Full Text] [Related]
3. Kaempferol ameliorated alcoholic liver disease through inhibiting hepatic bile acid synthesis by targeting intestinal FXR-FGF15 signaling.
Xiao L; Xu G; Chen S; He Y; Peng F; Yuan C
Phytomedicine; 2023 Nov; 120():155055. PubMed ID: 37678053
[TBL] [Abstract][Full Text] [Related]
4. Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency.
Huang M; Kong B; Zhang M; Rizzolo D; Armstrong LE; Schumacher JD; Chow MD; Lee YH; Joseph LB; Stofan M; Zhang L; Guo GL
Lab Invest; 2020 Sep; 100(9):1158-1168. PubMed ID: 32404932
[TBL] [Abstract][Full Text] [Related]
5. Altered ethanol metabolism and increased oxidative stress enhance alcohol-associated liver injury in farnesoid X receptor-deficient mice.
Morel C; Chowdhary V; Thevkar Nagesh P; Ribeiro M; Hawryluk D; Catalano D; Adorini L; Szabo G
Liver Int; 2023 Jan; 43(1):100-114. PubMed ID: 35869657
[TBL] [Abstract][Full Text] [Related]
6. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.
Wu WB; Chen YY; Zhu B; Peng XM; Zhang SW; Zhou ML
Biochimie; 2015 Aug; 115():86-92. PubMed ID: 26025474
[TBL] [Abstract][Full Text] [Related]
7. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.
Hartmann P; Hochrath K; Horvath A; Chen P; Seebauer CT; Llorente C; Wang L; Alnouti Y; Fouts DE; Stärkel P; Loomba R; Coulter S; Liddle C; Yu RT; Ling L; Rossi SJ; DePaoli AM; Downes M; Evans RM; Brenner DA; Schnabl B
Hepatology; 2018 Jun; 67(6):2150-2166. PubMed ID: 29159825
[TBL] [Abstract][Full Text] [Related]
9. Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice.
Fuchs CD; Krivanec S; Steinacher D; Mlitz V; Wahlström A; Stahlman M; Claudel T; Scharnagl H; Stojakovic T; Marschall HU; Trauner M
Liver Int; 2020 Jun; 40(6):1366-1377. PubMed ID: 32141703
[TBL] [Abstract][Full Text] [Related]
10. Gut-restricted apical sodium-dependent bile acid transporter inhibitor attenuates alcohol-induced liver steatosis and injury in mice.
Matye DJ; Li Y; Chen C; Chao X; Wang H; Ni H; Ding WX; Li T
Alcohol Clin Exp Res; 2021 Jun; 45(6):1188-1199. PubMed ID: 33885179
[TBL] [Abstract][Full Text] [Related]
11. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR.
Kong L; Dong R; Huang K; Wang X; Wang D; Yue N; Wang C; Sun P; Gu J; Luo H; Liu K; Wu J; Sun H; Meng Q
Phytomedicine; 2021 Sep; 90():153629. PubMed ID: 34304130
[TBL] [Abstract][Full Text] [Related]
12. Bruceine A alleviates alcoholic liver disease by inhibiting AIM2 inflammasome activation via activating FXR.
Li L; Xu S; Wang W; Li X; Wang H; Yang Q; Wang C; Gu J; Luo H; Meng Q
Phytomedicine; 2024 Jul; 130():155693. PubMed ID: 38763006
[TBL] [Abstract][Full Text] [Related]
13. Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation.
Sheng L; Jena PK; Liu HX; Kalanetra KM; Gonzalez FJ; French SW; Krishnan VV; Mills DA; Wan YY
Sci Rep; 2017 May; 7(1):1748. PubMed ID: 28496104
[TBL] [Abstract][Full Text] [Related]
14. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
[TBL] [Abstract][Full Text] [Related]
15. Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation.
Jiang M; Li F; Liu Y; Gu Z; Zhang L; Lee J; He L; Vatsalya V; Zhang HG; Deng Z; Zhang X; Chen SY; Guo GL; Barve S; McClain CJ; Feng W
Hepatology; 2023 Apr; 77(4):1164-1180. PubMed ID: 35689610
[TBL] [Abstract][Full Text] [Related]
16. S100A4 promotes inflammation but suppresses lipid accumulation via the STAT3 pathway in chronic ethanol-induced fatty liver.
Yuan Q; Hou S; Zhai J; Tian T; Wu Y; Wu Z; He J; Chen Z; Zhang J
J Mol Med (Berl); 2019 Oct; 97(10):1399-1412. PubMed ID: 31321478
[TBL] [Abstract][Full Text] [Related]
17. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
18. Curcumin attenuates ethanol-induced hepatic steatosis through modulating Nrf2/FXR signaling in hepatocytes.
Lu C; Zhang F; Xu W; Wu X; Lian N; Jin H; Chen Q; Chen L; Shao J; Wu L; Lu Y; Zheng S
IUBMB Life; 2015 Aug; 67(8):645-58. PubMed ID: 26305715
[TBL] [Abstract][Full Text] [Related]
19. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease.
Li Y; Chen M; Zhou Y; Tang C; Zhang W; Zhong Y; Chen Y; Zhou H; Sheng L
Theranostics; 2020; 10(8):3579-3593. PubMed ID: 32206109
[No Abstract] [Full Text] [Related]
20. Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor.
Tveter KM; Villa-Rodriguez JA; Cabales AJ; Zhang L; Bawagan FG; Duran RM; Roopchand DE
BMJ Open Diabetes Res Care; 2020 Aug; 8(1):. PubMed ID: 32771984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
